Multicenter, open-label, randomized study in patients with ovarian cancer
Phase of Trial: Phase II
Latest Information Update: 13 Jun 2017
At a glance
- Drugs Nivolumab (Primary) ; Doxorubicin; Gemcitabine
- Indications Ovarian cancer
- Focus Therapeutic Use
- Sponsors Ono Pharmaceutical
- 22 May 2017 Planned number of patients changed from 116 to 300.
- 22 May 2017 Planned End Date changed from 1 May 2019 to 1 Jul 2020.
- 22 May 2017 Status changed from active, no longer recruiting to recruiting.